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Discovery and use ofT cell growth factor, interleukin 2 (IL-2),  1 have made it possi- 
ble to immortalize functioning T  cells  and have facilitated studies on the activation, 
function, and antigen recognition of T  cells  (1-3). Human and murine neoplastic T 
cells  secreting  IL-2  have  been  particulary  useful  for  the  isolation  and  molecular 
characterization of IL-2 (4, 5). 
Recent studies with successful long-term culture of murine or human B cells  (6, 7) 
as well as with short-term B cell culture (8) have suggested the requirement of T  cell- 
derived growth factor(s)  for maintaining the continuous proliferation of activated B 
cells. Our studies with human leukemic B cells also showed that anti-immunoglobulin 
(anti-Ig) and growth factor were required for proliferation of B cells and three signals, 
anti-Ig, growth factor, and differentiation factor, were required for Ig production (9). 
However, little is known about B cell-specific growth factor (BCGF), and the lack of 
homogeneous BCGF preparations without IL-2 activity has hampered the establish- 
ment of nontransformed B cell lines. 
Previously, we showed the successful establishment of stable human T  hybridomas 
secreting several monoclonal immunoregulatory molecules involved in the prolifera- 
tion and differentiation of T  cells,  such as IL-2 or killer helper factor(s)  (10).  In the 
present study, we used a similar method for obtaining homogeneous factors involved 
in the proliferation or differentiation of B cells.  T  hybridomas secreting BCGF or B 
cell  differentiation  factor  (BCDF)  have been  established,  and  the  results  show the 
presence of molecular and functional heterogeneity in BCGF and the synergistic effect 
of two distinct  kinds of BCGF on the proliferation of B cells.  The results also show 
that  BCDF involved in the final  differentiation of B cells  into Ig-producing cells  is 
different from BCGF or IL-2. By using these monoclonal factors, activation process of 
B cells  into Ig-producing cells  are able to be dissected and reconstituted in vitro. 
* Supported in part by grants from the Ministry of Education, Science  and Culture, the Asahi Shinbun 
Science Foundation, the Mitsubishi Science Foundation, the Princess Takamatsu Cancer Fund, and the 
Naito Foundation. 
i Abbreviations used in  this paper: BCDF, B cell differentiation factor; BCGF, B cell growth factor; 
CEM-AG  R, azaguanine-resistant human T leukemic cell line, CEM; IL-1, IL-2, interleukin 1 and 2; PHA, 
phytohemagglutinin. 
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Materials  and  Methods 
Cells.  An azaguanine-resistant human T  cell line, CEM-AG  R, used for the establishment of 
T  hybridomas,  was described previously (10).  An  Epstein-Barr  virus-transformed  B  cell line, 
CESS, which was able to differentiate into IgG-producing cells in the presence of BCDF, has 
also been  described  (l 1).  An IL-2-dependent  human  cytotoxic T  cell line was established  by 
mixed lymphocyte reaction and maintained with IL-2 (12).  Normal B cells were isolated from 
human  peripheral  blood lymphocytes  (PBL)  after rosette  formation  with sheep  erythrocytes 
(SRBC) twice, and adherent cells were removed by dish adherence. 
Establishment of T Hybridomas.  The  method  used  has  been  described  (10).  T  cells isolated 
from  human  peripheral  blood  were  stimulated  with  protein  A  (10  /.tg/ml,  Pharmacia  Fine 
Chemicals Div. Of Pharmacia  Inc., Piscataway,  N J)  for 3 d  and  hybridized with CEM-AG  R 
cells. Hybrid cells were selected in hypoxanthine, aminopterin, thymidine (HAT) medium and 
cloned by a  limiting dilution method.  Hybrid clones were incubated  at  a  cell density of 1 X 
106/ml in RPMI  1640 with  10% fetal calf serum  (FCS)  (Centaurus,  Santa Ana, CA) for 48 h, 
cell-free  supernatants  were  recovered,  and  the  activities  of  BCGF,  BCDF,  and  IL-2  were 
assessed. 
Preparation of Conventional T Cell Factors.  l  X  106 purified peripheral T  cells were stimulated 
with 0.1% protein phytohemagglutinin  (PHA-P) for 48 h and partially purified by gel filtration 
on  Sephadex  G-100  in  0.5  M  Nacl.  Fractions  of  15,000-25,000  mol  wt  were  used,  and  the 
activity from  106 T  cells was defined as  1 U. 
Measurements ofBCGF, BCDF, and IL-2 Activities.  BCGF activity was assessed by using anti- 
#-stimulated B cells or B cells recovered from PHA-induced B cell colonies. 5 ×  104 nonadherent 
B  cells  in  0.2  ml  medium  (RPMI  1640  plus  10%  FCS)  were  stimulated  with  10  #g/ml  of 
affinity-purified rabbit anti-human IgM coupled to Sepharose 4B in the presence or absence of 
varying concentrations ofcuhure supernatants  from T  hybridomas. After 4 d culture, cells were 
3  3  pulsed with  1 #Ci of [ H]TdR for 5 h and the uptake of [ H]TdR was measured. 
For the assessment of the activity of the supernatants  to maintain the continuous growth of 
B cells, B cells from PHA-induced B colonies were used. The method of B cell colony formation 
was exactly the same as described (13).  2 X  106 B cells in 2 ml McCoy's 5A modified medium 
with  15% FCS and 5 ×  10 -5 M  2-mercaptoethanol were co-cultured with the same number of 
X-irradiated autologous T  cells and stimulated with PHA-P (1 : 1,600).  After 3 d  liquid culture, 
cells  were  harvested  and  transferred  to  soft  agar  cultures  with  double  layers  as  described 
previously (13).  After 7 d  culture in soft agar, colonies were picked up and cells were pooled. 
92% of pooled cells were positive for surface Ig by a direct immunofluorescent staining technique 
with fiuorescein isothiocyanate  (FITC)-conjugated  rabbit  anti-human  Ig  (Behringwerke AG, 
Marburg,  Federal  Republic  of Germany),  and  3.5%  of the  cells formed  SRBC  rosettes.  To 
remove T  cells, the pooled cells (2 ×  105) were treated with  100 #1 of the culture medium from 
anti-Leu-l-producing hybridomas,  a  gift of Dr.  R.  Evans  (Memorial Sloan-Kettering Cancer 
Center, New York)  and complement  (1:4 diluted newborn rabbit  serum).  1 X  103 B cells thus 
obtained from B colonies were incubated with 0.2 ml of supernatant  from T  hybrid clones for 
3 d, and 0.5 #Ci [3H]TdR was pulsed for 6 h. All cultures were set up in triplicate. 
BCDF activity in  the supernatants  was  detected  either by using CESS cells, which  could 
differentiate  into IgG-producing cells in  the presence  of BCDF  (11),  or Cowan  I-stimulated 
normal B cells (14).  1 X  104 CESS cells were incubated with 200 p~l of the supernatants  from T 
hybridomas for 48 h and the number of IgG-producing cells was enumerated by reverse plaque 
assay using protein A-coupled SRBC and anti-y antiserum.  BCDF activity for normal B cells 
was  measured  by using Cowan  I-stimulated normal  B  cells.  1 ×  106 purified  B  cells in  1 ml 
culture  medium  were  stimulated  with  0.0025%  Staphylococcus aureus Cowan  I  (Calbiochem- 
Behring Corp.,  La Jolla, CA).  After 3  d  culture,  cells were harvested  and  2  ×  105 cells were 
cultured  with  0.2  ml  supernatants  from  T  hybridomas  for  2  d.  IgG-producing  cells  were 
enumerated by reverse plaque assay. 
Activity of IL-2  in  the  supernatants  was  measured  by  using  an  IL-2-dependent  human 
cytotoxic T  cell line as described previously (12). 
Results 
THybridomas Secreting BCGF.  Over  I00 hybrid  clones were established  by hybrid- 
ization of protein  A-stimulated  peripheral  T  cells with CEM-AG R and  their culture OKADA ET AL.  58.5 
supernatants were tested for BCGF, BCDF,  and IL-2 activities. As shown  in Fig.  1, 
culture supernatants from three hybrid clones, 77-A, 94-C, and 98-F, augmented the 
proliferation of anti-IgM-stimulated B  cells.  The  activity of the  supernatants  was 
proportional  to  their  concentrations,  and  the  diluted  (1:124)  culture  supernatant 
obtained from  10  e of 77-A cells showed BCGF activity comparable to that  from  108 
PHA-stimulated normal T  cells, demonstrating that  BCGF activity from  77  A  cells 
was >100  times higher than  that  from PHA-stimulated normal T  cells. The culture 
supernatants from the three hybrid clones, 77-A, 94-C, and 98-F, however, showed no 
IL-2  activity  when  tested  with  an  IL-2-dependent  human  cytotoxic  T  cell  line. 
Moreover, a  hybrid clone 24-A, which had been shown to secrete IL-2 in our previous 
study (10), did not show BCGF activity. Taken collectively, these results clearly show 
that  the  molecules distinct  from  IL-2 were  involved in  the proliferation of anti-Ig- 
activated B cells. 
Existence of  Two  Distinct  BCGF  and  Their  Synergism.  To  study  whether  BCGF 
detected by anti-IgM-stimulated B  cells could maintain the continuous growth of B 
cells,  the  following  experiments  with  B  ceils  obtained  from  PHA-induced  B  cell 
colonies were carried out.  1 × 10 a B  cells obtained from PHA-induced B  cell colonies 
were cultured with 0.2  ml of supernatants  from hybrid clones and proliferation was 
assessed by [3H]TdR uptake. As shown in Figs.  1 and 2, the culture supernatant from 
77-A clone induced an increase in [3H]TdR uptake. On the other hand,  the culture 
supernatant  from 94-C clone, which augmented the proliferation of anti-IgM-stimu- 
lated B ceils, did not show any activity to induce the proliferation of colony-forming 
B  cells. The  result  suggested  the  presence  of two  distinct  kinds of BCGF,  i.e., one 
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FIo.  l.  BCGF, BCDF, and IL-2 activity m the culture supernatants  of human T hybrid clones. 
BCGF activity was assessed  by using anti-g-stimulated human peripheral B cells or B cells recovered 
from PttA-induced B colonies. BCGF activity in the  l:4-diluted culture supernatants  is shown 
(mean ± SE of triplicate cultures). BCDF activity in the supernatants  was detected by using either 
CESS cells or Cowan I-stimulated normal B cells. IgG producing cells were enumerated by reverse 
plaque assay. A PFC/cuhure = PFC/cuhure (factors[s] added) -  PFC/culture (no factor[s]). Mean 
±  SE of duplicate cultures  was shown. Background PFC without  factors were 217 and  1,185 in 
CESS cells and Cowan I-stimulated B cells, respectively. Semipurified PHA supernatant obtained 
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FIG. 2.  Synergistic  effect of two different BCGF on the continuous proliferation of B cells. Colony- 
forming  B cells were obtained from PHA-induced B colonies  as described in Materials and Methods. 
1,000 B cells were suspended in 0.2 ml of varying concentrations of the supernatants from 77-A  cells 
(O), 94-C cells (A), or in the mixture of the varying concentrations of 77-A supernatants and twofold 
dulution of 94-C supernatants (I)- After 3 d culture, 0.5 #Ci [aH]TdR was pulsed for 6 h and the 
uptake of [aH]TdR was measured. The activity of the supernatant from PHA-stimulated normal T 
cells (D) or the supernatant from CEM-AG  R cells (•)  was also measured. All cultures were done in 
triplicate and the mean _+ SE is shown. 
(77-A)  that  was  effective on  both  anti-lg-stimulated B  cells and  colony-forming B 
cells, and another (94-C) effective only on anti-Ig-stimulated B cells. 
The  most  interesting finding was  the  synergistic effect  of the  supernatants from 
77-A  and  94-C  cells  on  the  proliferation of colony-forming B  cells.  Although  the 
supernatant from 94-C did not induce any proliferation of colony-forming B cells, its 
addition to the supernatant from 77-A clone tremendously augmented the activity of 
77-A supernatant to  induce proliferation of colony-forming B  cells. The maximum 
proliferation of colony-forming  B cells was observed when 16-fold-diluted supernatant 
of 77-A cells was mixed with 2-fold-diluted supernatant of 94-C cells as shown in Fig. 
2. The addition of the supernatant of 90-E cells, which showed BCDF activity, to that 
of 77-A cells did not show any augmentation of [aH]TdR uptake by colony-forming 
B  cells. The addition of the 94-C supernatant to  that of 77-A cells also showed the 
synergistic effect on the proliferation of anti-#-stimulated B cells. However, the effect 
was  not  as  prominent  as  that  observed  in  colony-forming B  cells,  because  the 
supernatant of 94-C cells could itself induce the proliferation of anti-#-stimulated B 
cells. The result demonstrated the presence of two different kinds of BCGF and their 
synergistic effect on the proliferation of a  certain subset of B cells or of B  cells in a 
certain activation stage. 
Howard et al. (15)  reported that IL-1 from macrophages acted on anti-lg-activated 
B  cells to induce proliferation in a  synergistic manner with BCGF. To exclude the 
possibility that either clone 77-A or 94-C were hybridomas between macrophages and 
CEM-AG  R and secreted IL-1, surface phenotypes of the hybrid clones were analyzed 
using a  human monocyte-specific monoclonal antibody (16)  or a  monoclonal  anti- 
DR antibody (10). A macrophage cell line, U937, or a B cell line, CESS were used as 
a  positive control. Monocyte,specific antigens or DR antigens were not detected on 
either  77-A or 94-C  cells, suggesting that  77-A or  94-C  cells were  not  hybridomas 
between macrophages and a  T  cell line. Moreover, the supernatant of 94-C cells did 
not augment the proliferation of Con A-stimulated murine thymocytes, excluding the 
possibility that hybridomas secreted IL-1. OKADA  ET  AL.  587 
BCDF from  T  Hybridomas.  A  B  lymphoblastoid  cell  line,  CESS,  or  Cowan  I- 
stimulated normal B cells were used for the assessment of BCDF activity in the culture 
supernatants. CESS cells have been shown to differentiate directly into IgG-producing 
cells without any requirement of cell division when BCDF is provided (11).  As shown 
in  Fig.  1,  the culture supernatant  from clone 90-E  can  induce  an  increase in  IgG- 
producing cells in CESS cells or in Cowan I-stimulated normal B cells. The activity 
to induce IgG in CESS cells was dose dependent, but  1:8 diluted supernatant lost the 
activity.  When  the  supernatant  (1:2  dilution)  was  added  to  Cowan  I-stimulated 
normal  B  cells,  both  IgM-  and  IgG-producing  cells  were  induced,  i.e.,  705  IgM 
producing cells and 3,037 IgG producing cells per  l0  s cultured cells. Thus, the effect 
of 90-E supernatant  was not  isotype specific. The result  indicated  that  the culture 
supernatant  from clone 90-E was able to induce  final differentiation of B  lympho- 
blastoid  cells as well  as of normal  B  cells  into  Ig-secreting cells.  The same culture 
supernatant,  however, showed no BCGF or IL-2 activity. The culture supernatants 
from 77-A, 94-C, and 98-F, which showed BCGF activity, did not induce any increase 
in  IgG-producing cells  in  CESS  cells or Cowan  I-stimulated normal  B  cells.  From 
these results,  it appears that  BCGF is not  involved in  the final differentiation of B 
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F[o.  3.  Absorption of BCGF or BCDF activity with IL-2-dependent T  cells, CESS cells, or anti- 
/~-stimulated B cells. BCGF, BCDF in 1 ml of the culture supernatant from 1 X  106 of 77-A or 90-E 
cells, or IL-2 including 5 U of activity in  1 ml of PHA-supernatant were absorbed twice with  1 × 
107 IL-2-dependent T  cells and 2 ×  107 CESS cells for 2 h at 4°C, or once with 7 X 106 anti-~-B cells 
for 4 h  at 4°C. After absorption, activity of 1:20 diluted BCGF,  1:2 diluted BCDF, or 1:5 diluted 
IL-2 preparation was assessed with anti-#-stimulated B cells, CESS cells, or IL-2-dependent T  cells, 
respectively.  BCGF activity in the  1:20 diluted  nonabsorbed supernatant from 77-A cells,  BCDF 
activity in the 1:2 diluted supernatant from 90-E cells, and 1 U of IL-2 activity were shown as 100%. 588  B CELL GROWTH FACTORS FROM HUMAN T  ttYBRIDOMAS 
cells  and that the factor responsible for the differentiation of B cells  does not induce 
their proliferation. 
Absorption of BCGF or BCDF Activity by the  Target  Cells.  We confirmed that BCGF 
was a different molecule than IL-2 or BCDF using absorption experiments. As shown 
in Fig.  3,  1 ×  107 IL-2-dependent T  cells could absorb  1 U  of IL-2 activity from  106 
PHA-stimulated  T  cells,  whereas  the  same  number  of dependent  T  cells  did  not 
remove any BCGF activity in PHA supernatant or 77-A supernatant.  BCDF activity 
from  l0  G  90-E cells  was completely removed by the absorption with  2 ×  107 CESS 
cells, but the same absorption procedures did not remove any BCGF activity in 77-A 
supernatant. On the other hand, BCGF activity from  l0  G  77-A cells or 94-C cells was 
removed by the  absorption  with  0.7  ×  107  of anti-/z-stimulated  B  cells.  The  same 
number of anti-/z-stimulated B cells,  however, did not absorb BCDF activity in 90-E 
supernatant.  The result  showed the presence of acceptors specific for each factor on 
their target cells. 
Discussion 
The present  study showed the  successful establishment  of human T  hybridomas 
secreting monoclonal immunoregulatory molecules  involved  in  the  proliferation or 
differentiation  of B  cells.  The presence of the  B  cell-specific growth factor distinct 
from IL-2 has been suggested in murine and human system (7, 8).  Howard et al.  (8) 
demonstrated that a phorbol myristate acetate (PMA)-stimulated murine thymoma, 
EL-4, secreted BCGF that could be separated  from IL-2 by molecular sieving or by 
absorption  experiments.  In  the  human  system,  discrepancies  in  the  induction  of 
proliferation  of T  and  B  cells  in  the  culture supernatants  of mitogen-stimulated T 
cells  suggested  the  presence  of the  B  cell-specific growth  factor  (7). More  recently, 
absorption  experiments  (17) or  chromatographical separation  (18)  have  indicated 
that  BCGF and IL-2 are different molecules.  However, it  has not yet been demon- 
strated that BCGF or BCDF without IL-2 is sufficient to induce proliferation or final 
differentiation  of B  cells,  since  monoclonal BCGF  or  BCDF  preparations  without 
IL-2  or  other  lymphokine  activity  have  not  yet  been  obtained.  In  this  case,  T 
hybridomas secreting monoclonal immunoregulatory molecules proved powerful tools, 
and  the  results  herein  clearly  show  that  BCGF  distinct  from  IL-2  or  BCDF  was 
present and could induce B cell proliferation without any contamination of IL-2. 
Moreover, the present  result with  77-A and 94-C cells  showed the presence of the 
functional  heterogeneity  of BCGF  and  their  synergism  in  the  induction  of B  cell 
proliferation. In another experiment in our laboratory (19),  it was also demonstrated 
that an IL-2-dependent human helper T  cell clone secreted BCGF with the molecular 
weight of 50,000,  and  this BCGF showed an synergistic effect, with the  20,000-mol 
wt-BCGF, on the proliferation of anti-g-stimulated B cells. These results indicate the 
presence of at least two different kinds of BCGF. At moment, the cellular or molecular 
mechanism of the synergism between  the  two BCGF is  not known.  A  possibility is 
that one BCGF can act on B cells in Go phase and activate them into G1 phase, while 
another BCGF might push B cells  in G1 phase into S phase. If this is the case, those 
BCGF with distinct functions will  provide a  powerful strategy for the establishment 
of nontransforming B cell  lines. 
Absorption experiments shown in Fig. 3 clearly demonstrated the strict specificity 
between  T  cell-derived  factors and  their  target  cells.  IL-2-dependent T  cells  could OKADA ET AL.  589 
absorb IL-2 activity but not  BCGF activity, and BCGF activity was only absorbed 
with  anti-/t-stimulated  B  cells,  demonstrating  the  presence  of the  growth  factor(s) 
specific for T  or B  cells.  CESS  cells,  which  may represent  the  final  differentiation 
stage of B cells, could absorb BCDF but not BCGF activity, whereas anti-/t-stimulated 
B cells could not absorb BCDF activity, suggesting that acceptors for BCGF or BCDF 
may be expressed only in a certain activation stage of B cells. By the presence of such 
strict  specificity  between  acceptors  and  factors  and  the  temporal  expression  of 
acceptors, the specificity of the immune responses may be maintained  even if they 
were regulated by antigen-nonspecific factors. 
In the present experiments, both growth and differentiation factors for B cells were 
obtained from monoclonal T  cell hybridomas. In our preliminary experiment, anti- 
Ig, BCGF, and BCDF from hybrid clones could induce Ig production in leukemic B 
cells, demonstrating that these three signals could induce proliferation and differen- 
tiation  of a  certain subset of B  cells or B cells in a  certain activation stage into Ig- 
producing cells without  help from MHC-restricted T  cells. As our BCGF or BCDF 
did not  have any IL-2 activity, we can analyze the direct effect of the factors on B 
cells without worrying about the contamination ofT cells in the B cell fraction. Thus, 
by using those monoclonal factors, we will be able to dissect the activation process of 
B cells and to analyze the signals required for each step of the activation process. 
Summary 
Human T  hybridomas secreting B cell growth factors (BCGF) and B cell differen- 
tiation  factor  (BCDF)  have been  established.  Hybrid clones  77-A,  94-C,  and  98-F 
secreted BCGF that induced proliferation of anti-IgM-stimulated normal B cells. The 
culture supernatant  from 77-A cells could also maintain continuous proliferation of 
colony-forming B  cells,  but  the  factor  from  94-C  could  not.  The  addition  of the 
supernatant  from 94-C  cells  to  that  from  77-A  cells,  however,  synergistically aug- 
mented  the  proliferation  of colony-forming B  cells,  demonstrating  the  existence of 
two distinct  kinds of BCGF and  the synergism between  them. These supernatants, 
however, showed  no  interleukin  2  (IL-2)  or  BCDF  activity.  A  hybrid  clone,  90-E, 
secreted BCDF.  The culture supernatant  induced  Ig production  in Cowan I-stimu- 
lated normal B cells or in a transformed B cell line, CESS. However, the supernatant 
had no BCGF or IL-2 activity. Anti-Ig-stimulated B cells, but not IL-2-dependent T 
cells, absorbed BCGF activity and CESS cells absorbed BCDF activity but not BCGF 
activity in the culture supernatants from T  hybridomas. Taken collectively, the results 
demonstrated  that  IL-2, BCGF,  and  BCDF were different  molecules and acceptors 
specific for the each molecule are present on the each target cell. 
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